Arnaud Augert
Assistant ProfessorCards
About
Research
Publications
2021
Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas
Norton J, Augert A, Eastwood E, Basom R, Rudin C, MacPherson D. Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas. Genes & Development 2021, 35: 870-887. PMID: 34016692, PMCID: PMC8168556, DOI: 10.1101/gad.348316.121.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBasic Helix-Loop-Helix Transcription FactorsCarcinoma, Small CellCell DeathCell Line, TumorCOP9 Signalosome ComplexCyclopentanesDisease Models, AnimalGene Expression Regulation, NeoplasticHeterograftsHumansLung NeoplasmsMiceNEDD8 ProteinNeuroendocrine CellsProteinsPyrimidinesRepressor ProteinsSequence DeletionConceptsSmall cell lung carcinomaSmall cell carcinomaExtrapulmonary small cell carcinomaNeddylation inhibitionCell carcinomaCell statesGenome-scale CRISPR/Therapeutic targetPatient-derived xenograft modelsCell linesDeletion of componentsSolid tumor malignanciesCell lung carcinomaNovel therapeutic approachesPotential therapeutic targetSuppressor screenSCLC cell linesCOP9 signalosomeProtein neddylationCRISPR/Genetic suppressionPathway genesPDX modelsMajor regulatorLung carcinoma
2020
MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer.
Augert A, Mathsyaraja H, Ibrahim AH, Freie B, Geuenich MJ, Cheng PF, Alibeckoff SP, Wu N, Hiatt JB, Basom R, Gazdar A, Sullivan LB, Eisenman RN, MacPherson D. MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer. Cancer Cell 2020, 38: 97-114.e7. PMID: 32470392, DOI: 10.1016/j.ccell.2020.04.016.Peer-Reviewed Original Research
2019
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Augert A, Eastwood E, Ibrahim A, Wu N, Grunblatt E, Basom R, Liggitt D, Eaton K, Martins R, Poirier J, Rudin C, Milletti F, Cheng W, Mack F, MacPherson D. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Science Signaling 2019, 12 PMID: 30723171, PMCID: PMC6530478, DOI: 10.1126/scisignal.aau2922.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBasic Helix-Loop-Helix Transcription FactorsCell Line, TumorEnzyme InhibitorsGene Expression Regulation, NeoplasticHistone DemethylasesHumansKaplan-Meier EstimateLung NeoplasmsMice, Inbred NODMice, KnockoutMice, SCIDReceptors, NotchSignal TransductionSmall Cell Lung CarcinomaTumor BurdenXenograft Model Antitumor AssaysConceptsSmall cell lung cancerCell lung cancerNonsmall cell lung cancerLung cancerNotch activationLSD1 inhibitionPatient-derived xenograft modelsLSD1 inhibitorsReactivation of NotchFirst-line standardExpression of Ascl1Durable tumor regressionTranscription factor Ascl1Notch pathway activationLineage genesKnockdown studiesNotch pathwayDownstream signalingCare treatmentPDX modelsTumor regressionTargeted therapySCLC tumorigenesisActionable mutationsXenograft model
2018
Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition.
Jia D, Augert A, Kim DW, Eastwood E, Wu N, Ibrahim AH, Kim KB, Dunn CT, Pillai SPS, Gazdar AF, Bolouri H, Park KS, MacPherson D. Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 2018, 8: 1422-1437. PMID: 30181244, DOI: 10.1158/2159-8290.CD-18-0385.Peer-Reviewed Original Research
2017
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, Dowlati A, MacPherson D. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). J Thorac Oncol 2017, 12: 704-713. PMID: 28007623, DOI: 10.1016/j.jtho.2016.12.011.Peer-Reviewed Original Research
2016
The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action.
Griveau A, Devailly G, Eberst L, Navaratnam N, Le Calvé B, Ferrand M, Faull P, Augert A, Dante R, Vanacker JM, Vindrieux D, Bernard D. The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action. Oncogene 2016, 35: 5033-42. PMID: 27041564, DOI: 10.1038/onc.2016.43.Peer-Reviewed Original ResearchMultidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape.
Wiel C, Gras B, Vindrieux D, Warnier M, Gitenay D, Le Calvé B, Ferrand M, Augert A, Bernard D. Multidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape. Oncogene 2016, 35: 1596-601. PMID: 26073088, DOI: 10.1038/onc.2015.218.Peer-Reviewed Original Research
2014
Treating transcriptional addiction in small cell lung cancer.
Augert A, MacPherson D. Treating transcriptional addiction in small cell lung cancer. Cancer Cell 2014, 26: 783-784. PMID: 25490443, DOI: 10.1016/j.ccell.2014.11.012.Peer-Reviewed Original ResearchEndoplasmic reticulum calcium release through ITPR2 channels leads to mitochondrial calcium accumulation and senescence.
Wiel C, Lallet-Daher H, Gitenay D, Gras B, Le Calvé B, Augert A, Ferrand M, Prevarskaya N, Simonnet H, Vindrieux D, Bernard D. Endoplasmic reticulum calcium release through ITPR2 channels leads to mitochondrial calcium accumulation and senescence. Nat Commun 2014, 5: 3792. PMID: 24797322, DOI: 10.1038/ncomms4792.Peer-Reviewed Original ResearchPTEN is a potent suppressor of small cell lung cancer.
Cui M, Augert A, Rongione M, Conkrite K, Parazzoli S, Nikitin AY, Ingolia N, MacPherson D. PTEN is a potent suppressor of small cell lung cancer. Mol Cancer Res 2014, 12: 654-9. PMID: 24482365, DOI: 10.1158/1541-7786.MCR-13-0554.Peer-Reviewed Original Research